On October 20-21, the 2023 Annual Conference on Health Management of Hainan Medical Association was grandly held in Chengmai, Hainan. Guo Qing, Chairman of the Health Management Branch of the Chinese Medical Association, Zeng Qiang, Former Chairman, Liu Yuping, Vice Chairman Song Zhenya, Zhang Qun, and some provincial and municipal chairpersons such as Guo Zhiping, Wu Weiqing, Huang Hongwei, and more than 30 well-known experts and scholars in the field of health management including gathered in Hainan. Based on the actual development of health management in Hainan, the theme was "Focusing on disciplinary construction and precise prevention and treatment of chronic diseases". Through two sub forum platforms, "Discipline Construction and Innovative Development" and "Early Screening and Prevention of Cancer" via online and offline communication methods, focusing on "intelligent chronic disease management, health management discipline system construction, early screening and prevention of tumors, and quality control of physical examinations", participants explore the experience of chronic disease health management from different perspectives and fields, and discuss new concepts of health management development together.

On the afternoon of October 21st, at the sub forum on early screening and prevention of tumors, Professor Chen Xinping from Hainan Cancer Hospital and Professor Wu Weiqing from Shenzhen People's Hospital both emphasized in their relevant thematic reports that after screening and verifying through a thousand large sample and multicenter studies, seven miRNA biomarkers in plasma can effectively assist in the early diagnosis of liver cancer, especially for serum AFP negative populations (evidence level 1, recommendation A). The sensitivity and specificity of the miRNA7TM test kit for diagnosing liver cancer were 86.1% and 76.8% respectively. The sensitivity and specificity for AFP negative liver cancer were 77.7% and 84.5% respectively (evidence level 1, recommendation A). It has been included in multiple authoritative guidelines and consensus such as the Health Commission's "Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)".

The miRNA7^TM test kit can be applied in health management departments and clinical departments. In addition to screening for very early and early liver cancer, it can also be used in multiple scenarios such as regular monitoring of high-risk populations and recurrence detection of surgical patients. Due to the deficiency of traditional diagnostic and testing methods, liver cancer patients have not been able to achieve early detection and treatment in a timely manner. Most liver cancer patients are diagnosed in the middle and late stages, and the 5-year survival rate is much lower than other regions and countries. Real world data shows that for HCC patients with pathological diagnosis of BCLC stage 0, who receive testing for three items simultaneously, the detection rate of miRNA7TM in very early liver cancer is significantly higher than traditional detection methods such as AFP and DCP.

The liver cancer screening guidelines suggest that serum AFP is a commonly used and important indicator for diagnosing liver cancer and monitoring therapeutic effects. For serum AFP negative individuals, early diagnosis can be carried out using PIVKA II, miRNA test kits, AFP L3, and GALAD models. She believes that the application of miRNA7 in the field of liver cancer will greatly improve the 5-year survival rate of current liver cancer patients, hoping that such detection technology can be more widely practiced and used in clinical practice.

The overall goal of the "Healthy Hainan Action Implementation Plan" is to provide everyone with high-quality health services and high-level health security by 2030, significantly improve the level of public health, and achieve an average life expectancy of 82 years. This conference focuses on disciplinary construction and precise prevention and control, which has played a positive role in improving the early diagnosis and cure rates of tumors, and helping more people improve their awareness of health management. 

Efficient and accurate early detection technology for cancer has important clinical significance and social value in improving patient survival rate, reducing mortality rate, and reducing social burden. We believe that in the near future, benefiting from this innovative early detection technology will change the pattern of cancer diagnosis and treatment in China, and can further increase the average life expectancy in China.